Post-earnings recap
Reported
Thu, Apr 30, 2026
EPS actual
$2.60
EPS est.
$2.98
EPS surprise
-12.63%
1-day move
+0.00%
Stryker Corporation reported earnings that fell short of analyst expectations, particularly in EPS. Despite the miss, the stock showed no movement, remaining stable. Investors may be awaiting further insights from future earnings calls or additional guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.60 | $2.98 | -12.63% |
| Revenue | N/A | $6.3B | N/A |
No transcript is on record for this earnings call, so the analysis is based solely on the numerical results.
Stryker Corporation (SYK) is a leading medical technology company that develops and manufactures innovative healthcare equipment. Operating in the health care sector, Stryker focuses on products that enhance surgical outcomes and improve patient care, making it a significant player in the medical device industry.
Last quarter
In Q4-2025, Stryker reported an EPS of $4.47, beating estimates by 1.71%. However, the stock experienced a slight decline of 0.99% the following day.
EPS beat streak
1Q
EPS beat rate
88%
Avg EPS surprise
+1.29%
Avg 1-day reaction
-0.57%
Analysts expect Stryker to continue its trend of exceeding earnings expectations, with a consensus EPS of $2.98 and revenue of $6.3B. The market is closely watching for any signs of growth in demand for its products.
Bull case
If Stryker beats earnings expectations again, it could indicate strong operational efficiency and demand, potentially driving the stock higher as investors gain confidence in its growth trajectory.
Bear case
Conversely, if Stryker fails to meet expectations, it may raise concerns about market demand and profitability, leading to a negative reaction from investors.
Key metrics to watch
EPS
$2.98Earnings per share is a key indicator of profitability and will show how well Stryker is managing costs and generating income.
Revenue
$6.3BTotal revenue reflects the company's sales performance and market demand for its products, which is crucial for assessing growth.
The print will turn on these.
Q1
Will Stryker's EPS exceed the consensus estimate of $2.98?
A beat on EPS would reinforce Stryker's strong operational performance and could boost investor confidence.
Q2
What are the revenue growth prospects for Stryker's key product lines?
Understanding revenue growth will provide insight into market demand and the company's competitive position in the healthcare equipment sector.
—
Est. EPS
$1.94
Est. Rev
$3.0B
Impl. Move
±9.9%
Why consensus could be wrong
The Street may underestimate Stryker's ability to leverage its innovative product pipeline, which could lead to stronger-than-expected revenue growth this quarter.
Supporting evidence
Stryker has consistently beaten EPS estimates in the past, indicating strong operational execution.
The options market is pricing in a larger move than historical averages, suggesting that traders expect significant news.
Recent insider trading activity shows mixed signals, which may indicate uncertainty about future performance.
Key risk
If Stryker's revenue growth exceeds $6.5B, it could challenge the current cautious consensus.
Pre-commit to what would confirm each case.
This quarter, the focus is on Stryker's ability to maintain its growth trajectory amid competitive pressures and market dynamics.
Bull confirmed if
An EPS of $3.05 or higher would confirm the bull case, indicating strong demand and cost management.
Bear confirmed if
An EPS below $2.86 would confirm the bear case, suggesting potential issues with profitability or market demand.
What the market is pricing for the move.
Implied Move
±6.51%
Historical Avg
±0.8%
The options market is pricing in a significant move around the earnings report, suggesting that traders expect volatility based on the upcoming results.
Options are pricing ±6.5% while SYK has averaged ±0.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
19.6%
Smart-money positioning from the most recent 13F filings.
Institutional
82.77%
of float
Insider
5.36%
of float
Holders
3,033
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
27,414,742 sh · $7.6B
7.15%
-0.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Stryker beats expectations, history suggests the stock could rise by about 0.84%, confirming strong operational performance.
In line / cautious
An inline result may lead to a muted reaction, as investors await further guidance on future growth.
Miss
If Stryker misses expectations, the stock could decline, with historical patterns suggesting a potential drop of around 0.63%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
2
0 buys·2 sells
Members
1
House only
Est. Notional
$2,002.00–$30,000.00
disclosed dollar ranges
Most Active Members
2 trades
The lines on the call that would change the story.
Vanguard Capital Management LLC
22,536,843 sh · $6.2B
5.88%
0.7%
JPMORGAN CHASE & CO
17,260,943 sh · $4.8B
4.50%
10.7%
State Street Corporation
15,532,565 sh · $4.3B
4.05%
1.2%
Greenleaf Trust
15,228,545 sh · $4.2B
3.97%
-4.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Jul 22, 2026 · disclosed Aug 18, 2026
$1,001.00–$15,000.00
Traded Jun 2, 2026 · disclosed Jul 15, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.